secwatch.observer — SEC 8-K summary
======================================

Issuer:     Vivos Therapeutics, Inc. (VVOS)
CIK:        0001716166
Form:       8-K
Filed at:   2023-09-25T23:59:59+00:00
Accession:  0001493152-23-033544
Event type: other_material
Sentiment:  neutral
Materiality: 0.55
Item codes: 5.07
LLM model:  deepseek-v4-flash:cloud@v2

Vivos Therapeutics shareholders approve reverse stock split and increase in stock plan shares
--------------------------------------------------------------------------------

- Approved amendment to 2019 Stock Plan to increase authorized shares by 2,000,000 to 4,366,667 total.
- Approved reverse stock split at ratio between 1:10 and 1:30, with Board discretion on exact ratio.
- Elected six directors: Green, Krammer, Lindsay, Sokolow, Thompson, Huntsman for one-year terms.
- Ratified Moss Adams LLP as independent auditor for fiscal year ending Dec 31, 2023.
- Reverse split authorized by 12.7M votes for vs 5.7M against; stock plan approved by 6.0M for vs 5.4M against.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1716166/000149315223033544/0001493152-23-033544-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1716166/000149315223033544/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-23-033544

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer